Products
Ubamatamab Biosimilar Bispecific Antibody (MUC16 × CD3) for Research
Pre-Made Ubamatamab biosimilar, Whole mAb, Anti-MUC16;CD3E Antibody: Anti-CA125;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.Ubamatamab (formerly REGN 4018), a human bispecific antibody targeted against MUC16 (on tumour cells) and CD3 (on T cells), is being developed by Regeneron Pharmaceuticals for the treatment of ovarian cancer, fallopian tube cancer and peritoneal cancer.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-705-1mg | 1mg | |
| GMP-Bios-ab-705-10mg | 10mg | |
| GMP-Bios-ab-705-100mg | 100mg | |
| GMP-Bios-ab-705-xmg | ＞100mg |
Product Details
| Products Name (INN Index) | Pre-Made Ubamatamab biosimilar, Whole mAb, Anti-MUC16;CD3E Antibody: Anti-CA125;T3E/TCRE/IMD18 therapeutic antibody |
| INN Name | Ubamatamab |
| Target | MUC16;CD3E |
| Format | Bispecific Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG4;IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2021 |
| Year Recommended | na |
| Companies | Regeneron Pharmaceuticals |
| Conditions Approved | na |
| Conditions Active | Fallopian tube cancer;Ovarian cancer;Peritoneal cancer |
| Conditions Discontinued | na |
| Development Tech | na |
About target - MUC16
1. Protein Mucin-16
2. Gene MUC16
3. Organism Homo sapiens (Human)
Function
Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.
Miscellaneous
Antigen that is the basis for a widely used serum assay for the monitoring of patients with ovarian epithelial cancer. Due to lack of sensitivity for stage I disease and lack of specificity, it is of little value in the detection of early ovarian cancer. Due to its similarly elevated levels in some nonmalignant conditions, it is not specific enough to be used for population screening.
